Impact of SF3B1 mutation on outcomes in myelofibrosis.

被引:0
|
作者
Bose, Prithviraj
Senapati, Jayastu
Masarova, Lucia
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Pierce, Sherry
Zhou, Lingsha
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Verstovsek, Srdan
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
19080
引用
收藏
页数:1
相关论文
共 50 条
  • [21] PROTEOMIC ANALYSIS OF TERMINAL ERYTHROPOIESIS IN THE SF3B1 MUTATION MOUSE MODEL
    Tseng, Chun-Chih
    Metidji, Amina
    Wallace, LaShanale
    Yu, Kaiwen
    Wu, Long
    Engelken, Mark
    Cullins, David
    Myers, Jacquelyn
    Leal-Cervantes, Ana
    Wang, Xusheng
    High, Anthony
    Obeng, Esther
    EXPERIMENTAL HEMATOLOGY, 2024, 137
  • [22] IMMUNOPHENOTYPIC BONE MARROW CHARACTERISTICS IN MYELODYPLASTIC SYNDROME WITH SF3B1 MUTATION
    Souto, E.
    Bento, L.
    Velloso, E.
    Campregher, P.
    Fernandes, L.
    Nunes, V.
    Bacal, N.
    LEUKEMIA RESEARCH, 2023, 128
  • [23] Cooperation between SF3B1 mutation and ATM deletion in the development of CLL
    Wang, Lili
    Cusan, Martina
    Yin, Shanye
    Jin, Meiling
    Gutierrez, Catherine
    ten Hacken, Elisa
    Herman, Sarah
    Rassenti, Laura
    Ghia, Emanuela
    Kipps, Thomas J.
    Wiestner, Adrian
    Getz, Gad
    Siddiqi, Tanya
    Rosen, Steven
    Wu, Catherine J.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 264 - 265
  • [24] SF3B1 MUTATIONS AND THEIR IMPACT ON CELLULAR BIOENERGETICS IN MYELODYSPLASTIC SYNDROMES
    Hrustincova, A.
    Trsova, I.
    Krejcik, Z.
    Kundrat, D.
    Belickova, M.
    Kaisrlikova, M.
    Vesela, J.
    Klema, J.
    Rysavy, P.
    Suttnar, J.
    Hlavackova, A.
    Jonasova, A.
    Cermak, J.
    Merkerova, M. Dostalova
    LEUKEMIA RESEARCH, 2023, 128
  • [25] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    LABORATORY INVESTIGATION, 2014, 94 : 50A - 50A
  • [26] SF3B1 and SF3B3 Expression in Tamoxifen Resistance
    Gokmen-Polar, Y.
    Nellamraju, Y.
    Goswami, C. P.
    Gu, X.
    Janga, S. C.
    Badve, S.
    MODERN PATHOLOGY, 2014, 27 : 50A - 50A
  • [27] Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosis
    Xicoy, Blanca
    Pomares, Helena
    Morgades, Mireia
    Germing, Ulrich
    Arnan, Montserrat
    Tormo, Mar
    Palomo, Laura
    Orna, Elisa
    Della Porta, Matteo
    Schulz, Felicitas
    Diaz-Beya, Marina
    Esteban, Ada
    Molero, Antonieta
    Lanino, Luca
    Avendano, Alejandro
    Hernandez, Francisca
    Roldan, Veronica
    Ubezio, Marta
    Pineda, Alberto
    Diez-Campelo, Maria
    Zamora, Lurdes
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [28] SF3B1 Mutations in Hematological Malignancies
    Cilloni, Daniela
    Itri, Federico
    Bonuomo, Valentina
    Petiti, Jessica
    CANCERS, 2022, 14 (19)
  • [29] SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients
    T L Lasho
    C M Finke
    C A Hanson
    T Jimma
    R A Knudson
    R P Ketterling
    A Pardanani
    A Tefferi
    Leukemia, 2012, 26 : 1135 - 1137
  • [30] SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
    Malcovati, Luca
    Karimi, Mohsen
    Papaemmanuil, Elli
    Ambaglio, Ilaria
    Jadersten, Martin
    Jansson, Monika
    Elena, Chiara
    Galli, Anna
    Walldin, Gunilla
    Della Porta, Matteo G.
    Raaschou-Jensen, Klas
    Travaglino, Erica
    Kallenbach, Klaus
    Pietra, Daniela
    Ljungstrom, Viktor
    Conte, Simona
    Boveri, Emanuela
    Invernizzi, Rosangela
    Rosenquist, Richard
    Campbell, Peter J.
    Cazzola, Mario
    Lindberg, Eva Hellstrom
    BLOOD, 2015, 126 (02) : 233 - 241